Regeneron: Growth Catalysts Incoming
Regeneron Pharmaceuticals, Inc. is rated a Buy, supported by strong Dupixent and oncology growth offsetting Eylea/Eylea HD declines. REGN's robust pipeline, best-in-class products, and upcoming patent...
Fiscal Year: January - December
Regeneron Pharmaceuticals, Inc. (REGN), listed on the NASDAQ, has a market capitalization of $. As of Oct 04, 2025, the stock is trading at $600.00 per share, offering investors a clear view of its current market value. Regeneron Pharmaceuticals, Inc. is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 15.12, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Regeneron Pharmaceuticals, Inc. also offers a dividend yield of 0.59%, making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that Regeneron Pharmaceuticals, Inc. (REGN) may be undervalued compared to its intrinsic worth. However, to see the exact DCF fair value, please Login or Upgrade for access.
The proprietary SS Score for Regeneron Pharmaceuticals, Inc. is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Regeneron Pharmaceuticals, Inc., Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Regeneron Pharmaceuticals, Inc. is 16.14, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Regeneron Pharmaceuticals, Inc. (REGN) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Regeneron Pharmaceuticals, Inc. (REGN) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. Our analysis indicates that the stock may be undervalued compared to its intrinsic value. However, it is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Regeneron Pharmaceuticals, Inc. (REGN) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Regeneron Pharmaceuticals, Inc.. To access the full SS Score, consider upgrading your subscription.
Regeneron Pharmaceuticals, Inc. is a significant player in the industry sector, with a market capitalization of $ and a competitive P/E ratio of 15.12. Investors should compare these metrics with industry peers to gauge whether Regeneron Pharmaceuticals, Inc. is outperforming or underperforming within its sector.
Regeneron Pharmaceuticals, Inc. is rated a Buy, supported by strong Dupixent and oncology growth offsetting Eylea/Eylea HD declines. REGN's robust pipeline, best-in-class products, and upcoming patent...
TARRYTOWN, N.Y., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2025 financial and operating results on Tuesday...
Retail investors' fears over the launch of Eylea biosimilars are gradually fading amid the strong performance of Dupixent and Libtayo, actively gaining share in the PD-1 and PD-L1 inhibitors market. S...
FDA approval extends the indication of Evkeeza to treat younger patients with homozygous hypercholesterolemia (HoFH) HoFH is an inherited condition characterized by extremely high levels of low-densit...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum September 24, 2025 10:30 AM EDT Company Participants Ryan Crowe - Sen...
Regeneron Pharmaceuticals remains a top conviction idea, driven by strong Dupixent growth, a robust pipeline, and a healthy balance sheet. REGN's Q2 earnings showed solid revenue and EPS growth, with ...
Sanofi and Regeneron's Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion Recommendation for adults and adolescents based on phase 3 studies showing Dupixent sig...
Recommendation for adults and adolescents based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo
Regeneron said on Friday its experimental therapy showed either a complete or partial disappearance of a precancerous disorder, which manifests into blood cancer, in all patients in a mid-stage trial.
Inmazeb ® (atoltivimab, maftivimab, and odesivimab-ebgn) was the first treatment approved by the U.S. Food and Drug Administration (FDA) for Orthoebolavirus zairense , also known as Zaire ebolavirus
Regeneron Pharmaceuticals said on Wednesday its experimental treatment for a rare genetic disorder that affects bone tissue has met the main goal of a late-stage trial.
FOP is a disease in which muscles, tendons and ligaments are progressively replaced by bone, leading to eventual incapacitation
Late-breaking data from exploratory analyses at WCLC show Libtayo plus chemotherapy demonstrates a more than double five-year overall survival rate of 19.4%, compared to 8.8% with chemotherapy alone
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 7:00 AM EDT Company Participants Christopher Fenimore - Executive VP of Finance...
Regeneron Pharmaceuticals, Inc. REGN revealed data from Phase 3 trials in adults with moderate-to-severe cat or birch allergies on Monday. Both trials met their respective primary and key secondary en...
TARRYTOWN, N.Y., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today that it will now present at the Morgan Stanley 23rd Annual Global Healthcare Conferen...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 9:30 AM EDT Company Participants Ryan Crowe - Senior Vice President of Investor Rela...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Cantor Global Healthcare Conference 2025 September 3, 2025 1:35 PM EDT Company Participants Ryan Crowe - Senior Vice President of Investor Relations & St...
Regeneron Pharmaceuticals, Inc. shares have lost >50% of their value over the past 12 months. Regeneron remains a powerhouse pharma however, despite threats to its key drug Eylea from generics and lon...
Regeneron Pharmaceuticals said on Tuesday its experimental therapy for treating patients with a rare immune disorder has met the main goal of a late-stage study.
Cemdisiran monotherapy, dosed subcutaneously every three months, met the primary and key secondary endpoints, showing a 2.3-point placebo-adjusted improvement in Myasthenia Gravis Activities of Daily ...
Fujifilm Biotechnologies will open a new biologics manufacturing plant in the U.S. this fall, with Regeneron and Johnson & Johnson as the initial customers. The Holly Springs, North Carolina, site is ...
TARRYTOWN, N.Y., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has extended the target action dates ...
Below estimates were sourced from SimplyWallSt and are intended for educational purposes only as a baseline for the analysis.
Year | FCF Estimate | % | # Analysts |
---|---|---|---|
2025 | 3.97B | 8.21% | Est @8.2% |
2026 | 4.27B | 7.59% | Analyst x4 |
2027 | 4.88B | 14.46% | Analyst x3 |
2028 | 5.48B | 12.29% | Analyst x3 |
2029 | 6.02B | 9.78% | Analyst x3 |
2030 | 6.33B | 5.20% | Est @5.2% |
2031 | 6.61B | 4.34% | Est @4.3% |
2032 | 6.85B | 3.73% | Est @3.7% |
2033 | 7.08B | 3.30% | Est @3.3% |
2034 | 7.28B | 2.81% | Est @2.8% |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
Year | FCF | Discount Factor | PV of Future FCF |
---|---|---|---|
2023A | 3.88B | 1.00 | 3.88B |
2024A | 3.66B | 1.00 | 3.66B |
2025E | 3.97B | 1.07 | 3.69B |
2026E | 4.27B | 1.15 | 3.70B |
2027E | 4.88B | 1.24 | 3.95B |
2028E | 5.48B | 1.33 | 4.13B |
2029E | 6.02B | 1.42 | 4.23B |
2030E | 6.33B | 1.53 | 4.14B |
2031E | 6.61B | 1.64 | 4.03B |
2032E | 6.85B | 1.76 | 3.89B |
2033E | 7.08B | 1.89 | 3.74B |
2034E | 7.28B | 2.03 | 3.59B |
Terminal | 154.40B | 2.03 | 76.09B |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.